Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials

KIZ OpenIR > 其他

	Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials
	Zhu, YM; Gao, ZC; Feng, XL; Hu, Y; Liu, N; Liu, C; Yang, QJ; Zou, QC; Li, MH; Song, GS; He, YX
	2025
发表期刊	Antiviral Res.
ISSN	0166-3542
卷号	237
摘要	IPB29 is a lipopeptide-based coronavirus fusion inhibitor with the potent, broad-spectrum antiviral activity, and it has already been advanced to phase III clinical trials for the treatment of SARS-CoV-2 infection. We recently reported its design strategy and initial preclinical characterization; herein, we focused on characterizing its efficacies against newly-emerged Omicron variants, as well as its chronic general toxicity, toxicokinetics, immunogenicity, and reproductive toxicity in animal models. As anticipated, IPB29 demonstrated improved activity in inhibiting JN.1 and KP.2 variants, effectively blocking cell fusion and pseudovirus infections. Nebulized inhalation of IPB29 exhibited high therapeutic efficacy against live BA.5 and EG.5.1 infections in Syrian hamsters. The 26-week toxicity studies revealed that nebulized IPB29 has a favorable safety profile, with wellcharacterized toxicokinetics in SD rats and Beagle dogs. Notably, short-term nebulization of IPB29 did not elicit anti-drug antibody (ADA) responses in either species. However, IPB29-specific antibodies were detected after long-term administration. Finally, a three-stage reproductive toxicity study in SD rats indicated that IPB29 had no significant toxic effects on fertility, embryo-fetal development, or the development of offspring. In summary, our findings demonstrate that IPB29 is a safe and effective SARS-CoV-2 inhibitor with promising potential for clinical applications.
收录类别	SCIE
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/15150
专题	其他
推荐引用方式 GB/T 7714	Zhu, YM,Gao, ZC,Feng, XL,et al. Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials[J]. Antiviral Res.,2025,237.
APA	Zhu, YM.,Gao, ZC.,Feng, XL.,Hu, Y.,Liu, N.,...&He, YX.(2025).Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.Antiviral Res.,237.
MLA	Zhu, YM,et al."Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials".Antiviral Res. 237(2025).

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2026071370.pdf（11490KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文